Clinical Trial Results:
Multicenter, double-blind, parallel-group, randomised, 48 weeks, dose-ranging, placebo-controlled phase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of BI456906 in patients with non-alcoholic steatohepatitis (NASH) and fibrosis
Summary
|
|
EudraCT number |
2020-002723-11 |
Trial protocol |
FR BE NL PT CZ DE HU AT GR PL IT |
Global end of trial date |
21 Dec 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Jan 2025
|
First version publication date |
02 Jan 2025
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
1404-0043
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04771273 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Boehringer Ingelheim
|
||
Sponsor organisation address |
Binger Strasse 173, Ingelheim am Rhein, Germany, 55216
|
||
Public contact |
Boehringer Ingelheim, Call Center, Boehringer Ingelheim, 001 18002430127, clintriage.rdg@boehringer-ingelheim.com
|
||
Scientific contact |
Boehringer Ingelheim, Call Center, Boehringer Ingelheim, 001 18002430127, clintriage.rdg@boehringer-ingelheim.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
02 Feb 2024
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
09 Nov 2023
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
21 Dec 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary trial objectives were to demonstrate a non-flat dose response curve, to evaluate the size of the treatment effect (using the absolute difference in proportions of patients with NASH and fibrosis that show histological improvement between Survodutide [BI 456906] and placebo treatment at Week 48), and to characterize the dose-response relationship.
|
||
Protection of trial subjects |
Only subjects that met all the study inclusion and none of the exclusion criteria were to be entered in the study. All subjects were free to withdraw from the clinical trial at any time for any reason given. Close monitoring of all subjects was adhered to throughout the trial conduct. Rescue medication was allowed for all subjects as required.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
07 Jul 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
China: 58
|
||
Country: Number of subjects enrolled |
Hong Kong: 14
|
||
Country: Number of subjects enrolled |
Japan: 77
|
||
Country: Number of subjects enrolled |
Korea, Republic of: 10
|
||
Country: Number of subjects enrolled |
Taiwan: 13
|
||
Country: Number of subjects enrolled |
Austria: 7
|
||
Country: Number of subjects enrolled |
Belgium: 1
|
||
Country: Number of subjects enrolled |
Czechia: 8
|
||
Country: Number of subjects enrolled |
France: 9
|
||
Country: Number of subjects enrolled |
Germany: 43
|
||
Country: Number of subjects enrolled |
Greece: 11
|
||
Country: Number of subjects enrolled |
Hungary: 12
|
||
Country: Number of subjects enrolled |
Italy: 22
|
||
Country: Number of subjects enrolled |
Netherlands: 11
|
||
Country: Number of subjects enrolled |
Poland: 78
|
||
Country: Number of subjects enrolled |
Portugal: 6
|
||
Country: Number of subjects enrolled |
Spain: 27
|
||
Country: Number of subjects enrolled |
United Kingdom: 26
|
||
Country: Number of subjects enrolled |
Canada: 17
|
||
Country: Number of subjects enrolled |
United States: 632
|
||
Country: Number of subjects enrolled |
Australia: 17
|
||
Country: Number of subjects enrolled |
Israel: 12
|
||
Country: Number of subjects enrolled |
Malaysia: 16
|
||
Country: Number of subjects enrolled |
New Zealand: 13
|
||
Country: Number of subjects enrolled |
Singapore: 13
|
||
Worldwide total number of subjects |
1153
|
||
EEA total number of subjects |
235
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
937
|
||
From 65 to 84 years |
216
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment details |
This was a trial in patients with non-alcoholic steatohepatitis (NASH). Main parameters for inclusion of patients and for evaluation of treatment response were based on the histological evaluation from the liver biopsy and non-invasive imaging modalities. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Screening details |
All subjects were screened for eligibility prior to participation in the trial. Patients who met the eligibility criteria at an initial screening visit had a second screening visit for biopsy to confirm their eligibility, if no sufficient material from a historical biopsy within the 6 months prior to randomisation was available. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Period 1 title |
Randomisation period
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Carer, Data analyst, Assessor | ||||||||||||||||||||||||||||||||||||||||||||||||||
Blinding implementation details |
This trial has a double-blind design across dose groups. Patients, investigators, central reviewers, and everyone involved in trial conduct or analysis or with any other interest in this double-blind trial (except for an interim analysis which was performed for internal planning purposes by an independent team within the sponsor) remained blinded with regard to the randomised treatment assignments until after the main database lock.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Survodutide 2.4 mg - planned maintenance treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3). were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 2.4 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Survodutide 4.8 mg - planned maintenance treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3). were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 4.8 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Survodutide 6.0 mg - planned maintenance treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3). were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 6.0 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Placebo - planned maintenance treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3). were administered once weekly, subcutaneously a solution for injection of placebo matching survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Period 2
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Period 2 title |
Dose Escalation + Maintenance Periods
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes [1] | ||||||||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Carer, Data analyst, Assessor | ||||||||||||||||||||||||||||||||||||||||||||||||||
Blinding implementation details |
This trial has a double-blind design across dose groups. Patients, investigators, central reviewers, and everyone involved in trial conduct or analysis or with any other interest in this double-blind trial (except for an interim analysis which was performed for internal planning purposes by an independent team within the sponsor) remained blinded with regard to the randomised treatment assignments until after the main database lock.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Survodutide 2.4 mg - planned maintenance treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 2.4 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Survodutide
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
BI 456906
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 2.4 mg of survodutide.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Survodutide 4.8 mg - planned maintenance treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 4.8 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Survodutide
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
BI 456906
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3). were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 4.8 mg of survodutide.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Survodutide 6.0 mg - planned maintenance treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 6.0 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Survodutide
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
BI 456906
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3). were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 6.0 mg of survodutide.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Placebo - planned maintenance treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were administered once weekly, subcutaneously a solution for injection of placebo matching survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo to match BI 456906
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3). were administered once weekly, subcutaneously a solution for injection of placebo matching survodutide.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period. Justification: In this period the subjects who were randomized in this trial are reported. The baseline characteristics are not reported for the randomized subjects but for the treated subjects. |
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: Out of 1153 subjects screened only 293 subjects were treated. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Survodutide 2.4 mg - planned maintenance treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 2.4 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Survodutide 4.8 mg - planned maintenance treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 4.8 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Survodutide 6.0 mg - planned maintenance treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 6.0 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo - planned maintenance treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were administered once weekly, subcutaneously a solution for injection of placebo matching survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Survodutide 2.4 mg - actual maintenance treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
This arm includes patients who were treated with 2.4 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period.
This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 2.4 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Survodutide 4.8 mg - actual maintenance treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
This arm includes patients who were treated with 4.8 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period.
This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 4.8 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Survodutide 6.0 mg - actual maintenance treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
This arm includes patients who were treated with 6.0 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period.
This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 6.0 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Placebo - actual maintenance treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
This arm includes patients who were treated with placebo matching survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period.
This arm includes also those patients who were receiving placebo matching survodutide administered weekly and who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Survodutide 2.4 mg - planned maintenance treatment
|
||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3). were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 2.4 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||
Reporting group title |
Survodutide 4.8 mg - planned maintenance treatment
|
||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3). were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 4.8 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||
Reporting group title |
Survodutide 6.0 mg - planned maintenance treatment
|
||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3). were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 6.0 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||
Reporting group title |
Placebo - planned maintenance treatment
|
||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3). were administered once weekly, subcutaneously a solution for injection of placebo matching survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). | ||
Reporting group title |
Survodutide 2.4 mg - planned maintenance treatment
|
||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 2.4 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||
Reporting group title |
Survodutide 4.8 mg - planned maintenance treatment
|
||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 4.8 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||
Reporting group title |
Survodutide 6.0 mg - planned maintenance treatment
|
||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were to be administered once weekly, subcutaneously a solution for injection of survodutide at a starting dose of 0.3 milligrams (mg) followed by a dose escalation up to the maintenance dose of 6.0 mg of survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). Patients not tolerating the assigned dose due to gastrointestinal adverse events had the option of a dose adjustment which could lead to a maintenance dose lower than the dose the patient was randomized to. | ||
Reporting group title |
Placebo - planned maintenance treatment
|
||
Reporting group description |
Patients with non-alcoholic steatohepatitis (NASH) with non-alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥4 and fibrosis stage 1-3 (F1-F3) were administered once weekly, subcutaneously a solution for injection of placebo matching survodutide. The total treatment duration was 48 weeks (consisting of up to 24 weeks dose escalation period and at least 24 weeks maintenance period). | ||
Subject analysis set title |
Survodutide 2.4 mg - actual maintenance treatment
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
This arm includes patients who were treated with 2.4 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period.
This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 2.4 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.
|
||
Subject analysis set title |
Survodutide 4.8 mg - actual maintenance treatment
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
This arm includes patients who were treated with 4.8 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period.
This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 4.8 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.
|
||
Subject analysis set title |
Survodutide 6.0 mg - actual maintenance treatment
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
This arm includes patients who were treated with 6.0 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period.
This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 6.0 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.
|
||
Subject analysis set title |
Placebo - actual maintenance treatment
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
This arm includes patients who were treated with placebo matching survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period.
This arm includes also those patients who were receiving placebo matching survodutide administered weekly and who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.
|
|
|||||||||||||||||||||
End point title |
Improvement (yes/ no) from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment in patients with NASH (NAS ≥ 4, fibrosis F1-F3) - actual maintenance treatment | ||||||||||||||||||||
End point description |
Percentage of patients who had an improvement from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment is reported. Percentages were rounded to one decimal place.
Improvement in histological findings was defined as a composite of improvement in NASH and no worsening of fibrosis.
Improvement in non-alcoholic steatohepatitis (NASH) was defined as decrease of at least 2 points in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) with at least 1 point decrease in NAS subscore of either lobular inflammation or ballooning.
Patients without post-baseline data were considered non-responders.
Patients are analyzed according to the actual treatment they received at the start of the dose maintenance period (for patients who reached the maintenance period) or the next maintenance dose up from the dose at treatment discontinuation (for patients who discontinued treatment prior to the maintenance period).
|
||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||
End point timeframe |
At baseline and at 48 weeks.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-2.4 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included actual treatment, presence of diabetes of any type and Baseline Fibrosis Score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [1] | ||||||||||||||||||||
P-value |
= 0.001 [2] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
3.47
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
1.66 | ||||||||||||||||||||
upper limit |
7.25 | ||||||||||||||||||||
Notes [1] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 2.4 mg" vs. "Placebo". [2] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-4.8 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included actual treatment, presence of diabetes of any type and Baseline Fibrosis Score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 4.8 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
148
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [3] | ||||||||||||||||||||
P-value |
< 0.0001 [4] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
9.52
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
4.35 | ||||||||||||||||||||
upper limit |
20.85 | ||||||||||||||||||||
Notes [3] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 4.8 mg" vs. "Placebo". [4] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-6.0 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included actual treatment, presence of diabetes of any type and Baseline Fibrosis Score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
131
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [5] | ||||||||||||||||||||
P-value |
< 0.0001 [6] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
7.07
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
3.1 | ||||||||||||||||||||
upper limit |
16.16 | ||||||||||||||||||||
Notes [5] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 6.0 mg" vs. "Placebo". [6] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod linear model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [7] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod linear model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [7] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept, and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. Linear model fit assumption. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod exponential-1 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [8] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod exponential-1 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [8] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept, and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. MCP-Mod exponential-1 model assumption: 25% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod exponential-2 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [9] | ||||||||||||||||||||
P-value |
= 0.0008 | ||||||||||||||||||||
Method |
MCP-Mod exponential -2 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [9] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. MCP-Mod exponential-2 model assumption: 5% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod Emax1 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [10] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod Emax1 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [10] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. MCP-Mod Emax1 model assumption: 50% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod Emax2 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [11] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod Emax2 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [11] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. MCP-Mod Emax2 model assumption: 80% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod quadratic model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [12] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod quadratic model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [12] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. MCP-Mod quadratic model assumption: Maximum effect is achieved at dose 4.8 mg. |
|
|||||||||||||||||||||
End point title |
Improvement (yes/ no) from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment in patients with NASH (NAS ≥ 4, fibrosis F1-F3) - planned maintenance treatment | ||||||||||||||||||||
End point description |
Percentage of patients who had an improvement from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment is reported. Percentages were rounded to one decimal place.
Improvement in histological findings was defined as a composite of improvement in non-alcoholic steatohepatitis (NASH) and no worsening of fibrosis.
Improvement in NASH was defined as decrease of at least 2 points in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) with at least 1 point decrease in NAS subscore of either lobular inflammation or ballooning.
Patients without post-baseline data were considered non-responders.
Patients are analyzed for this endpoint according to the planned treatment (planned maintenance dose strength) they were assigned at randomisation even if patients did not reach the maintenance period at all, and therefore did not "settle" on any maintenance dose.
|
||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||
End point timeframe |
At baseline and after 48 weeks of treatment.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-2.4 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model includes planned treatment, presence of diabetes of any type and Baseline Fibrosis Score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
147
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [13] | ||||||||||||||||||||
P-value |
< 0.0001 [14] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
5.49
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
2.46 | ||||||||||||||||||||
upper limit |
12.28 | ||||||||||||||||||||
Notes [13] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 2.4 mg" vs. "Placebo". [14] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-6.0 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model includes planned treatment, presence of diabetes of any type and Baseline Fibrosis Score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
148
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [15] | ||||||||||||||||||||
P-value |
= 0.0001 [16] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
4.87
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
2.18 | ||||||||||||||||||||
upper limit |
10.91 | ||||||||||||||||||||
Notes [15] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 6.0 mg" vs. "Placebo". [16] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod linear model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [17] | ||||||||||||||||||||
P-value |
= 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod linear model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [17] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. Linear model fit assumption. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-4.8 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model includes planned treatment, presence of diabetes of any type and Baseline Fibrosis Score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 4.8 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
146
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [18] | ||||||||||||||||||||
P-value |
< 0.0001 [19] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
10.14
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
4.49 | ||||||||||||||||||||
upper limit |
22.87 | ||||||||||||||||||||
Notes [18] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 4.8 mg" vs. "Placebo". [19] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod exponential-1 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [20] | ||||||||||||||||||||
P-value |
= 0.0115 | ||||||||||||||||||||
Method |
MCP-Mod exponential-1 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [20] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept, and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. Model assumption: 25% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod exponential-2 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [21] | ||||||||||||||||||||
P-value |
= 0.2204 | ||||||||||||||||||||
Method |
MCP-Mod exponential-2 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [21] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept, and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. Model assumption: 5% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod Emax1 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [22] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod Emax1 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [22] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept, and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. Model assumption: 50% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod Emax2 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [23] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod Emax2 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [23] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. Model assumption: 80% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod quadratic model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the Multiple Comparison Procedure - Modelling (MCP-Mod) approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [24] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod quadratic model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [24] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept, and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors. P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed. Model assumption: Maximum effect is achieved at dose 4.8 mg. |
|
|||||||||||||||||||||
End point title |
Improvement of liver fat content (yes/ no) defined as at least 30% relative reduction in liver fat content after 48 weeks of treatment compared to baseline assessed by MRI-PDFF - actual maintenance treatment | ||||||||||||||||||||
End point description |
Percentage of participants with improvement in liver fat content is reported. Improvement in liver fat content was defined as percentage reduction from baseline of ≥30% in liver fat content after 48 weeks of treatment compared to baseline. Percentages were rounded to one decimal place.
Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF).
Patients without post-baseline values were imputed as non-responders.
Treated set - actual maintenance treatment. Patients are analyzed according to the actual treatment they received at the start of the dose maintenance period (for patients who reached the maintenance period) or the next maintenance dose up from the dose at treatment discontinuation (for patients who discontinued treatment prior to the maintenance period).
Number of patients analyzed reflects the number of patients included in the analysis model.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At baseline and after 48 weeks.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-2.4 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included actual treatment, presence of diabetes of any type, baseline liver fat content and baseline fibrosis score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [25] | ||||||||||||||||||||
P-value |
< 0.0001 [26] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
5.07
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
2.47 | ||||||||||||||||||||
upper limit |
10.4 | ||||||||||||||||||||
Notes [25] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 2.4 mg" vs. "Placebo". [26] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-6.0 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included actual treatment, presence of diabetes of any type, baseline liver fat content and baseline fibrosis score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
131
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [27] | ||||||||||||||||||||
P-value |
< 0.0001 [28] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
16.09
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
6.69 | ||||||||||||||||||||
upper limit |
38.73 | ||||||||||||||||||||
Notes [27] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 6.0 mg" vs. "Placebo". [28] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod linear model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [29] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod linear model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [29] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. Linear model fit assumption. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod quadratic model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [30] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod quadratic model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [30] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. MCP-Mod quadratic model assumption: Maximum effect is achieved at dose 4.8 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod exponential-2 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [31] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod exponential-2 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [31] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept, and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. MCP-Mod exponential-2 model assumption: 5% of maximum effect achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod Emax1 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [32] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod Emax1 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [32] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. MCP-Mod Emax1 model assumption: 50% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod Emax2 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [33] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod Emax2 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [33] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept, and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. MCP-Mod Emax2 model assumption: 80% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-4.8 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included actual treatment, presence of diabetes of any type, baseline liver fat content and baseline fibrosis score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 4.8 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
148
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [34] | ||||||||||||||||||||
P-value |
< 0.0001 [35] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
9.46
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
4.36 | ||||||||||||||||||||
upper limit |
20.51 | ||||||||||||||||||||
Notes [34] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 4.8 mg" vs. "Placebo". [35] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod exponential-1 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Survodutide 4.8 mg - actual maintenance treatment v Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [36] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod exponential-1 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [36] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept, and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. MCP-Mod exponential-1 model assumption: 25% of maximum effect is achieved at dose 3.0 mg. |
|
|||||||||||||||||||||
End point title |
Improvement of liver fat content (yes/ no) defined as at least 30% relative reduction in liver fat content after 48 weeks of treatment compared to baseline assessed by MRI-PDFF - planned maintenance treatment | ||||||||||||||||||||
End point description |
Percentage of participants with improvement in liver fat content is reported. Improvement in liver fat content was defined as percentage reduction from baseline of ≥30% in liver fat content after 48 weeks of treatment compared to baseline.
Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF).
Patients without post-baseline values were imputed as non-responders.
Patients are analyzed for this endpoint according to the planned treatment (planned maintenance dose strength) they were assigned at randomisation even if patients did not reach the maintenance period at all, and therefore did not "settle" on any maintenance dose.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At baseline and at 48 weeks.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod linear model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [37] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod linear model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [37] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept, and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. Linear model fit assumption. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-6.0 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included planned treatment, presence of diabetes of any type, baseline liver fat content and baseline fibrosis score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
148
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [38] | ||||||||||||||||||||
P-value |
< 0.0001 [39] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
8.22
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
3.66 | ||||||||||||||||||||
upper limit |
18.5 | ||||||||||||||||||||
Notes [38] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 6.0 mg" vs. "Placebo". [39] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-4.8 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included planned treatment, presence of diabetes of any type, baseline liver fat content and baseline fibrosis score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 4.8 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
146
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [40] | ||||||||||||||||||||
P-value |
< 0.0001 [41] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
12.06
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
5.3 | ||||||||||||||||||||
upper limit |
27.45 | ||||||||||||||||||||
Notes [40] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 4.8 mg" vs. "Placebo". [41] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-2.4 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included planned treatment, presence of diabetes of any type, baseline liver fat content and baseline fibrosis score. Firth’s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
147
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [42] | ||||||||||||||||||||
P-value |
< 0.0001 [43] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
10.39
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
4.6 | ||||||||||||||||||||
upper limit |
23.45 | ||||||||||||||||||||
Notes [42] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 2.4 mg" vs. "Placebo". [43] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod Emax2 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [44] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod Emax2 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [44] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. MCP-Mod Emax2 model assumption: 80% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod Emax1 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [45] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod Emax1 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [45] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. MCP-Mod Emax1 model assumption: 50% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod exponential-2 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [46] | ||||||||||||||||||||
P-value |
= 0.0925 | ||||||||||||||||||||
Method |
MCP-Mod exponential-2 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [46] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. MCP-Mod exponential-2 model assumption: 5% of maximum effect is achieved at dose 3.0 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod quadratic model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [47] | ||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||
Method |
MCP-Mod quadratic model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [47] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept, and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. MCP-Mod quadratic model assumption: Maximum effect is achieved at dose 4.8 mg. |
|||||||||||||||||||||
Statistical analysis title |
MCP-Mod exponential-1 model fit | ||||||||||||||||||||
Statistical analysis description |
A flat vs. non-flat dose-response relationship across the 3 doses of survodutide and placebo was tested using the MCP-Mod approach which evaluated simultaneously 6 different plausible dose-response patterns (linear, exponential1, exponential2, Emax1, Emax2, quadratic) while keeping full control of the type I error (one-sided alpha of 0.050).
P-values from the contrast tests corresponding to each dose response pattern evaluated were adjusted for the multiple comparisons performed.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Survodutide 4.8 mg - planned maintenance treatment v Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
293
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [48] | ||||||||||||||||||||
P-value |
= 0.0031 | ||||||||||||||||||||
Method |
MCP-Mod exponential-1 model fit | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [48] - Logistic regression estimates were used as input for the MCP-Mod. The logistic regression model was fitted without an intercept and included presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3] and the dose group as factors, and baseline liver fat content (assessed by MRI-PDFF) as a continuous linear covariate. MCP-Mod exponential-1 model assumption: 25% of maximum effect is achieved at dose 3.0 mg. |
|
|||||||||||||||||||||
End point title |
Absolute change of liver fat content from baseline after 48 weeks of treatment assessed by MRI-PDFF - actual maintenance treatment | ||||||||||||||||||||
End point description |
Absolute change of liver fat content (percentage [%]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF).
Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
Patients are analyzed according to the actual treatment they received at the start of the dose maintenance period (for patients who reached the maintenance period) or the next maintenance dose up from the dose at treatment discontinuation
(for patients who discontinued treatment prior to the maintenance period). Number of patients analyzed reflects the number of patients included in the analysis model.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
MMRM - 2.4 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [49] | ||||||||||||||||||||
P-value |
< 0.0001 [50] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-8.59
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-10.59 | ||||||||||||||||||||
upper limit |
-6.6 | ||||||||||||||||||||
Notes [49] - No confirmatory hypothesis testing was performed. The number of subjects in this analysis included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 2.4 mg"- Least Squares Mean of "Placebo". [50] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MMRM - 6.0 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
124
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [51] | ||||||||||||||||||||
P-value |
< 0.0001 [52] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-11.07
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-13.23 | ||||||||||||||||||||
upper limit |
-8.92 | ||||||||||||||||||||
Notes [51] - No confirmatory hypothesis testing was performed. The number of subjects in this analysis included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 6.0 mg"- Least Squares Mean of "Placebo". [52] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MMRM - 4.8 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 4.8 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [53] | ||||||||||||||||||||
P-value |
< 0.0001 [54] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-10.91
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-12.96 | ||||||||||||||||||||
upper limit |
-8.86 | ||||||||||||||||||||
Notes [53] - No confirmatory hypothesis testing was performed. The number of subjects in this analysis included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 4.8 mg"- Least Squares Mean of "Placebo". [54] - The p−value reported is considered nominal. |
|
|||||||||||||||||||||
End point title |
Absolute change of liver fat content from baseline after 48 weeks of treatment assessed by MRI-PDFF - planned maintenance treatment | ||||||||||||||||||||
End point description |
Absolute change of liver fat content from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF).
Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
Patients are analyzed for this endpoint according to the planned treatment (planned maintenance dose strength) they were assigned at randomisation even if patients did not reach the maintenance period at all, and therefore did not "settle" on any maintenance dose. Number of patients analyzed reflects the number of patients included in the analysis model.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
MMRM - 2.4 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
130
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [55] | ||||||||||||||||||||
P-value |
< 0.0001 [56] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-9.12
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-11.21 | ||||||||||||||||||||
upper limit |
-7.03 | ||||||||||||||||||||
Notes [55] - No confirmatory hypothesis testing was performed. The number of subjects "in this analysis" included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 2.4 mg"- Least Squares Mean of "Placebo". [56] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MMRM - 6.0 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
127
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [57] | ||||||||||||||||||||
P-value |
< 0.0001 [58] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-10.86
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-13 | ||||||||||||||||||||
upper limit |
-8.73 | ||||||||||||||||||||
Notes [57] - No confirmatory hypothesis testing was performed. The number of subjects "in this analysis" included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 6.0 mg"- Least Squares Mean of "Placebo". [58] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MMRM - 4.8 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 4.8 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [59] | ||||||||||||||||||||
P-value |
< 0.0001 [60] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-10.79
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-12.85 | ||||||||||||||||||||
upper limit |
-8.73 | ||||||||||||||||||||
Notes [59] - No confirmatory hypothesis testing was performed. The number of subjects "in this analysis" included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 4.8 mg"- Least Squares Mean of "Placebo". [60] - The p−value reported is considered nominal. |
|
|||||||||||||||||||||
End point title |
Percent change of liver fat content from baseline after 48 weeks of treatment assessed by MRI-PDFF - actual maintenance treatment | ||||||||||||||||||||
End point description |
Percent change of liver fat content (percentage [%]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF).
Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
Patients are analyzed according to the actual treatment they received at the start of the dose maintenance period (for patients who reached the maintenance period) or the next maintenance dose up from the dose at treatment discontinuation (for patients who discontinued treatment prior to the maintenance period). Number of patients analyzed reflects the number of patients included in the analysis model.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
MMRM - 2.4 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [61] | ||||||||||||||||||||
P-value |
< 0.0001 [62] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-43.64
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-53.49 | ||||||||||||||||||||
upper limit |
-33.79 | ||||||||||||||||||||
Notes [61] - No confirmatory hypothesis testing was performed. The number of subjects in this analysis included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 2.4 mg"- Least Squares Mean of "Placebo". [62] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MMRM - 4.8 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 4.8 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [63] | ||||||||||||||||||||
P-value |
< 0.0001 [64] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-55.52
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-65.61 | ||||||||||||||||||||
upper limit |
-45.42 | ||||||||||||||||||||
Notes [63] - No confirmatory hypothesis testing was performed. The number of subjects in this analysis included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 4.8 mg"- Least Squares Mean of "Placebo". [64] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MMRM - 6.0 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
124
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [65] | ||||||||||||||||||||
P-value |
< 0.0001 [66] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-57.02
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-67.66 | ||||||||||||||||||||
upper limit |
-46.39 | ||||||||||||||||||||
Notes [65] - No confirmatory hypothesis testing was performed. The number of subjects in this analysis included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 6.0 mg"- Least Squares Mean of "Placebo". [66] - The p−value reported is considered nominal. |
|
|||||||||||||||||||||
End point title |
Percent change of liver fat content from baseline after 48 weeks of treatment assessed by MRI-PDFF - planned maintenance treatment | ||||||||||||||||||||
End point description |
Percent change of liver fat content (percentage [%]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF).
Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
Patients are analyzed for this endpoint according to the planned treatment (planned maintenance dose strength) they were assigned at randomisation even if patients did not reach the maintenance period at all, and therefore did not "settle" on any maintenance dose. Only patients which were included in the analysis model of this endpoint are reported.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
MMRM - 2.4 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
130
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [67] | ||||||||||||||||||||
P-value |
< 0.0001 [68] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-46.49
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-56.74 | ||||||||||||||||||||
upper limit |
-36.25 | ||||||||||||||||||||
Notes [67] - No confirmatory hypothesis testing was performed. The number of subjects in this analysis included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 2.4 mg"- Least Squares Mean of "Placebo". [68] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MMRM - 4.8 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 4.8 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [69] | ||||||||||||||||||||
P-value |
< 0.0001 [70] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-55.11
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-65.25 | ||||||||||||||||||||
upper limit |
-44.98 | ||||||||||||||||||||
Notes [69] - No confirmatory hypothesis testing was performed. The number of subjects in this analysis included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 4.8 mg"- Least Squares Mean of "Placebo". [70] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
MMRM - 6.0 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
Least Squares Mean differences and 95% confidence interval were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type [yes, no], baseline fibrosis score [F1, F2, F3], visit, treatment by visit interaction and baseline by visit interaction as factors.
|
||||||||||||||||||||
Comparison groups |
Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
127
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [71] | ||||||||||||||||||||
P-value |
< 0.0001 [72] | ||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||||
Point estimate |
-56.26
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-66.76 | ||||||||||||||||||||
upper limit |
-45.77 | ||||||||||||||||||||
Notes [71] - No confirmatory hypothesis testing was performed. The number of subjects in this analysis included all the subjects for an MMRM analysis, in which all subjects contribute to variability and covariance matrix estimates, even if not part of the pairwise comparison being presented, i.e.,252 subjects. Mean Difference (Net) was calculated as: Least Squares Mean of "Survodutide 6.0 mg"- Least Squares Mean of "Placebo". [72] - The p−value reported is considered nominal. |
|
|||||||||||||||||||||
End point title |
Improvement of fibrosis (yes/ no) defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy - actual maintenance treatment | ||||||||||||||||||||
End point description |
Percentage of participants with improvement of liver fibrosis is reported.
Improvement of fibrosis was defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy.
The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease and the stages of fibrosis based on their location are the following:
- 1A Zone 3, perisinusoidal, delicate;
- 1B Zone 3, perisinuosoidal, dense;
- 1C Portal, periportal only;
- 2 Zone 3, perisinusoidal + portal, periportal only;
- 3 Bridging fibrosis;
- 4 Cirrhosis.
For analysis purposes no distinction was made between stages 1A, 1B and 1C.
Patients are analyzed according to the actual treatment they received at the start of the dose maintenance period (for patients who reached the maintenance period) or the next maintenance dose up from the dose at treatment discontinuation (for patients who discontinued treatment prior to the maintenance period).
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At baseline and after 48 weeks of treatment.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-2.4 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included actual treatment, presence of diabetes of any type and baseline fibrosis score. Firth‘s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [73] | ||||||||||||||||||||
P-value |
= 0.1894 [74] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
1.61
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
0.79 | ||||||||||||||||||||
upper limit |
3.26 | ||||||||||||||||||||
Notes [73] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 2.4 mg" vs. "Placebo". [74] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-6.0 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included actual treatment, presence of diabetes of any type and baseline fibrosis score. Firth‘s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 6.0 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
131
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [75] | ||||||||||||||||||||
P-value |
= 0.0028 [76] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
3.37
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
1.52 | ||||||||||||||||||||
upper limit |
7.45 | ||||||||||||||||||||
Notes [75] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 6.0 mg" vs. "Placebo". [76] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-4.8 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included actual treatment, presence of diabetes of any type and baseline fibrosis score. Firth‘s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 4.8 mg - actual maintenance treatment v Placebo - actual maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
148
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [77] | ||||||||||||||||||||
P-value |
= 0.0685 [78] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
2
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
0.95 | ||||||||||||||||||||
upper limit |
4.2 | ||||||||||||||||||||
Notes [77] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 4.8 mg" vs. "Placebo". [78] - The p−value reported is considered nominal. |
|
|||||||||||||||||||||
End point title |
Improvement of fibrosis (yes/ no) defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy - planned maintenance treatment | ||||||||||||||||||||
End point description |
Percentage of participants with improvement of liver fibrosis is reported.
Improvement of fibrosis was defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy.
The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease and the stages of fibrosis based on their location are the following:
- 1A Zone 3, perisinusoidal, delicate;
- 1B Zone 3, perisinuosoidal, dense;
- 1C Portal, periportal only;
- 2 Zone 3, perisinusoidal + portal, periportal only;
- 3 Bridging fibrosis;
- 4 Cirrhosis.
For analysis purposes no distinction was made between stages 1A, 1B and 1C.
Patients are analyzed for this endpoint according to the planned treatment (planned maintenance dose strength) they were assigned at randomisation even if patients did not reach the maintenance period at all, and therefore did not "settle" on any maintenance dose.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At baseline and after 48 weeks of treatment.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-2.4 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included planned treatment, presence of diabetes of any type and baseline fibrosis score. Firth‘s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 2.4 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
147
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [79] | ||||||||||||||||||||
P-value |
= 0.0663 [80] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
2.02
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
0.95 | ||||||||||||||||||||
upper limit |
4.27 | ||||||||||||||||||||
Notes [79] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 2.4 mg" vs. "Placebo". [80] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-4.8 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included planned treatment, presence of diabetes of any type and baseline fibrosis score. Firth‘s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 4.8 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
146
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [81] | ||||||||||||||||||||
P-value |
= 0.0672 [82] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
2.01
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
0.95 | ||||||||||||||||||||
upper limit |
4.23 | ||||||||||||||||||||
Notes [81] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 4.8 mg" vs. "Placebo". [82] - The p−value reported is considered nominal. |
|||||||||||||||||||||
Statistical analysis title |
Logistic regression-6.0 mg Survodutide vs. Placebo | ||||||||||||||||||||
Statistical analysis description |
The logistic regression model included planned treatment, presence of diabetes of any type and baseline fibrosis score. Firth‘s penalized regression was used.
The logistic regression model included all 293 treated subjects, not just those allocated to the two compared treatment groups.
|
||||||||||||||||||||
Comparison groups |
Survodutide 6.0 mg - planned maintenance treatment v Placebo - planned maintenance treatment
|
||||||||||||||||||||
Number of subjects included in analysis |
148
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [83] | ||||||||||||||||||||
P-value |
= 0.0512 [84] | ||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||
Point estimate |
2.11
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
1 | ||||||||||||||||||||
upper limit |
4.46 | ||||||||||||||||||||
Notes [83] - No confirmatory hypothesis testing was performed. Odds Ratio of "Survodutide 6.0 mg" vs. "Placebo". [84] - The p−value reported is considered nominal. |
|
|||||||||||||||||||||
End point title |
Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy - actual maintenance treatment | ||||||||||||||||||||
End point description |
Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy is reported.
The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease.
Patients are analyzed according to the actual treatment they received at the start of the dose maintenance period (for patients who reached the maintenance period) or the next maintenance dose up from the dose at treatment discontinuation (for patients who discontinued treatment prior to the maintenance period). Number of patients analyzed reflects the number of patients included in the analysis model.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At baseline and 48 weeks of treatment.
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy - planned maintenance treatment | ||||||||||||||||||||
End point description |
Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy is reported.
The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease.
Patients are analyzed for this endpoint according to the planned treatment (planned maintenance dose strength) they were assigned at randomisation even if patients did not reach the maintenance period at all, and therefore did not "settle" on any maintenance dose.
Only patients with NAS at baseline and at 48 weeks after treatment are included in the analysis.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At baseline and 48 weeks of treatment.
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
[All-Cause Mortality], [Serious Adverse Events], [Other Adverse Events]: From first study drug administration until last study drug administration plus 28 days of residual effect period (REP), up to 365 days.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Adverse events are reported according to the actual treatment the patents received at the start of the dose maintenance phase (for patients who reached the maintenance period) or the next maintenance dose up from the dose at treatment discontinuation (for patients who discontinued treatment prior to the maintenance period).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
26.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Survodutide 2.4 mg - actual maintenance treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
This arm includes patients who were treated with 2.4 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period. This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 2.4 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
This arm includes patients who were treated with placebo matching survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period. This arm includes also those patients who were receiving placebo matching survodutide administered weekly and who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Survodutide 6.0 mg - actual maintenance treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
This arm includes patients who were treated with 6.0 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period. This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 6.0 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Survodutide 4.8 mg - actual maintenance treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
This arm includes patients who were treated with 4.8 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period. This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 4.8 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
18 Dec 2020 |
Global protocol amendment No. 1 - Part 1:
Regular self-monitoring blood glucose (SMBG) measurements in type 2 diabetes mellitus (T2DM) patients on antidiabetic medication and safety measures in case of hypoglycaemic events were added at request from Health Authority. Dispensation of SMBG device was implemented as an additional safety measure.
Unplanned data monitoring committee (DMC) meeting and unblinded safety assessment by DMC at the occurrence of adverse events that might lead to trial discontinuation were added at request from Health Authority regarding trial stopping criteria and process.
Inclusion criterion body mass index (BMI) cut-off increased to 25 kg/m2 to homogenously include overweight patients of all ethnicities. The previous BMI cut-off included normal weight Caucasians or overweight Asians.
Exclusion criteria modified:
Estimated glomerular filtration rate (eGFR) cut-off increased to 60 mL/min/1.73m2 (at request from Health Authority).
Exclusion of patients with history of organ transplantation except for corneal transplantation (at request from Health Authority).
For patients with history of major depressive disorder in the past 2 years, the criterion “requiring inpatient treatment or escalation of care” was added for identification of patients with history of major depressive disorder. |
||
18 Dec 2020 |
Global protocol amendment No. 1 - Part 2:
Trial treatment discontinuation criteria modified:
Occurrence of an adverse event (AE) Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 related to trial treatment added to the trial treatment discontinuation criteria for individual patients.
Information regarding close monitoring and medical review of all AEs CTCAE Grade 3 and higher added as triggers for discontinuation of trial treatment for all patients.
Minimum requirement for collection of liver biopsy specimen (i.e. size of biopsy needle, size of biopsy specimen) added to define the quality standards for an accurate histology evaluation
Clarification added to exclude patients from sites in China for collection of blood samples for exploratory biomarkers, but Fib-4 index and aspartate amino transferase (AST) to platelet ratio index (APRI) were to be calculated.
Guidelines for removal of individual patients in case of increased liver enzymes revised, and trial treatment discontinuation criteria defined for individual patients in the event of drug-induced liver injury, at request from Health Authority. |
||
14 May 2021 |
Global protocol amendment No. 2:
Cap for patients from sites in China removed:
Definition of full analysis set amended to omit the reference to China. Sensitivity analysis of the primary endpoint including patients from sites in China removed. Description of interim analysis modified to include patients from sites in China.
Screening period extended to 10 weeks, as central assessments might take longer than 8 weeks.
Vital signs at Visit 1a became optional, as measurement at the primary site on the day of the screening biopsy might not be always possible. Requirement to perform imaging assessments at the same time of the day removed.
Urine pregnancy test at Follow-Up Visit added, pregnancy test should be performed at the end of the relevant systemic exposure.
Exclusion criteria modified:
Fasting condition was no longer required for blood samples collection at any visit. However, serum triglycerides might be retested at fasting condition during screening if the levels at Visit 1 exceeded 500 mg/dL (5.65 mmol/L).
Congestive heart failure New York Heart Association (NYHA) class III-IV added to align with trials using the same compound.
Treatment discontinuation criteria modified:
Torsade de Pointes and any major adverse cardiovascular events added at request from Health Authority.
Clinically significant elevation of liver enzymes and tolerance issues added for completeness (this information was already mentioned in other sections).
Information from toxicology studies relevant to selection of 6 mg dose added at request from Health Authority.
Paper Instructions for Use, paper diary, and paper PRO questionnaires added as a backup solution in case electronic documents were not available.
Option to conduct safety laboratory tests in local laboratories added to ensure trial continuity while maintaining patient safety in the event of disruptive circumstances. |
||
24 May 2022 |
Global Protocol amendment No. 3 - Part 2:
Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitors removed from the list of restricted concomitant medications, there are no clinical justifications for complete exclusion of T2DM patients treated with SGLT-2 inhibitors.
Medications known to significantly prolong the QT/QTc interval added as restricted concomitant medications, to align with exclusion criterion #15.
Requirement to repeat FibroScan® and MR imaging at re-screening removed, if the initial screening was performed within a month, to reduce burden for patients.
Guidelines for removal of individual patients in case of increased liver enzymes revised, to align with the consensus guidelines including provisions for patients with Gilbert’s syndrome.
Note: upon submission of CTP version 4.0 dated 24 May 2022 Boehringer Ingelheim (BI) received advice from the FDA to: (1) implement non-invasive tests and/or imaging tools in non-cirrhotic subjects with low platelet count in order to exclude portal hypertension, and (2) exclude patients who
recently started treatment with an SGLT-2 inhibitor. As the trial was in the final stage of recruitment and the implementation of additional tests and tools would require more time than the remaining time for recruitment, it was decided that clinical trial protocol (CTP) version 4.0 dated 24 May 2022 was not implemented. |
||
24 May 2022 |
Global Protocol amendment No. 3 - Part 1:
Inclusion criterion modified: liver biopsy findings should always be the primary assessment if histology and non-invasive assessments differed, as liver biopsy is more accurate in staging and grading NASH and liver fibrosis than FibroScan® and Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF).
Screening period extended if logistical issues caused delays for results of liver biopsy from central vendor(s). Eligible patients could be considered for trial participation even if results were received more than 10 weeks after Visit 1 (ethical aspect).
Exclusion criteria:
eGFR cut-off modified to include patients with mild or moderate renal impairment, as recent findings indicated no safety concerns for these patients.
Platelet count cut-off modified: liver cirrhosis was ruled out by histology, therefore patients without any sign of liver cirrhosis and a platelet count >110 x 10^9/L assumably have a non-significant risk of portal hypertension.
Stopping rules of the trial modified: instead of stopping the trial treatment in all patients, enrolment of new patients was to be stopped pending DMC recommendation, as sudden stop and possible restart of the trial treatment in all patients might lead to drug tolerability issues in many patients.
Criteria for Grade 3 CTCAE AEs of nausea, vomiting, diarrhoea, constipation, or anorexia specified: evaluation the CTCAE grading was put into a more clinically meaningful context to be considered for stopping enrolment of new patients and potentially stopping the trial following DMC recommendation. |
||
04 Aug 2022 |
Global Protocol amendment No. 4:
Platelet count cut-off changed back to the original level, as the trial was in the final stage of recruitment and implementation of alternative non-invasive tests and/or
imaging tools for the exclusion of portal hypertension as requested by Health Authority would require more time than the remaining recruitment time.
Patients recently started on SGLT-2 inhibitors excluded as recommended by Health Authority. |
||
27 Jul 2023 |
Global Protocol amendment No. 5:
Information on purpose of the interim analysis and access to unblinded data from the interim analysis modified, as data on liver fat reduction and liver benefits from this trial were essential for developing the Phase III program for Survodutide in chronic weight management. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |